Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000008308 | SCV000932417 | pathogenic | Familial hemophagocytic lymphohistiocytosis 5 | 2024-02-23 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 477 of the STXBP2 protein (p.Pro477Leu). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This missense change has been observed in individuals with hemophagocytic lymphohistiocytosis (PMID: 19804848, 19884660). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 7858). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on STXBP2 protein function. Experimental studies have shown that this missense change affects STXBP2 function (PMID: 19804848, 19884660). For these reasons, this variant has been classified as Pathogenic. |
Revvity Omics, |
RCV000008308 | SCV002021982 | pathogenic | Familial hemophagocytic lymphohistiocytosis 5 | 2020-04-21 | criteria provided, single submitter | clinical testing | |
Genomic Medicine Center of Excellence, |
RCV000008308 | SCV003924323 | pathogenic | Familial hemophagocytic lymphohistiocytosis 5 | 2023-05-08 | criteria provided, single submitter | research | |
Baylor Genetics | RCV000008308 | SCV004205629 | pathogenic | Familial hemophagocytic lymphohistiocytosis 5 | 2023-12-27 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000008308 | SCV000028515 | pathogenic | Familial hemophagocytic lymphohistiocytosis 5 | 2010-09-01 | no assertion criteria provided | literature only | |
Biochemical Molecular Genetic Laboratory, |
RCV000008308 | SCV001133011 | pathogenic | Familial hemophagocytic lymphohistiocytosis 5 | 2019-09-15 | no assertion criteria provided | clinical testing | |
Prevention |
RCV003924815 | SCV004743960 | pathogenic | STXBP2-related disorder | 2023-11-30 | no assertion criteria provided | clinical testing | The STXBP2 c.1430C>T variant is predicted to result in the amino acid substitution p.Pro477Leu. This variant has been reported to be pathogenic in several patients with familial hemophagocytic lymphohistiocytosis (FHL) and may be associated with early onset, severe forms of FHL (zur Stadt et al. 2009. PubMedID: 19804848; Cote et al. 2009, PubMedID: 19884660; Cetica et al. 2010. PubMedID: 20798128). This variant is reported in 0.0052% of alleles in individuals of East Asian descent in gnomAD. This variant is interpreted as pathogenic. |